Sumanirole

Sumanirole
Clinical data
ATC code	none;
Identifiers
	IUPAC name (R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one;
CAS Number	179386-43-7 ; 179386-44-8 (maleate);
PubChem CID	9818479;
IUPHAR/BPS	3949;
ChemSpider	7994229;
UNII	3E93IV1U45;
ChEMBL	ChEMBL419792;
CompTox Dashboard (EPA)	DTXSID00870144 ;
Chemical and physical data
Formula	C11H13N3O
Molar mass	203.240 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC3Cn1c2c(C3)cccc2nc1=O;

Sumanirole (PNU-95,666) is a highly selective D₂ receptor full agonist, the first of its kind to be discovered.^[1]^[2]^[3] It was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for medical use ^[4]^[5] it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D2-linked (vs. D1, D3, D4, and D5-linked) mechanism of action.^[3]

In 2004, Pfizer announced the end of their clinical development program for sumanirole, citing “recent studies that failed to sufficiently distinguish sumanirole from currently available therapies”.^[6]

References

^ Romero AG, et al. Synthesis of the selective D2 receptor agonist PNU-95666E from D-phenylalanine using a sequential oxidative cyclization strategy. Journal of Organic Chemistry. 1997; 62(19):6582.
^ McCall RB, Lookingland KJ, Bédard PJ, Huff RM (September 2005). "Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1248–56. doi:10.1124/jpet.105.084202. PMID 15980060.
^ ^a ^b Weber M, Chang WL, Breier MR, Yang A, Millan MJ, Swerdlow NR (March 2010). "The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20 (6): 421–425. doi:10.1016/j.euroneuro.2010.02.011. PMC 2864324. PMID 20346635.
^ Barone P, Lamb J, Ellis A, Clarke Z (March 2007). "Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society. 22 (4): 483–9. doi:10.1002/mds.21191. PMID 17115380.
^ Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, Layton G, Versavel M (March 2007). "Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study". Sleep Medicine. 8 (2): 119–27. doi:10.1016/j.sleep.2006.05.018. PMID 17239657.
^ Pfizer, Inc. "Pfizer to Discontinue Sumanirole Development Program". Parkinson's Disease Foundation.

[1] Romero AG, et al. Synthesis of the selective D2 receptor agonist PNU-95666E from D-phenylalanine using a sequential oxidative cyclization strategy. Journal of Organic Chemistry. 1997; 62(19):6582.

[pmid15980060-2] McCall RB, Lookingland KJ, Bédard PJ, Huff RM (September 2005). "Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1248–56. doi:10.1124/jpet.105.084202. PMID 15980060.

[pmid20346635-3] Weber M, Chang WL, Breier MR, Yang A, Millan MJ, Swerdlow NR (March 2010). "The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20 (6): 421–425. doi:10.1016/j.euroneuro.2010.02.011. PMC 2864324. PMID 20346635.

[pmid17115380-4] Barone P, Lamb J, Ellis A, Clarke Z (March 2007). "Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society. 22 (4): 483–9. doi:10.1002/mds.21191. PMID 17115380.

[pmid17239657-5] Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, Layton G, Versavel M (March 2007). "Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study". Sleep Medicine. 8 (2): 119–27. doi:10.1016/j.sleep.2006.05.018. PMID 17239657.

[6] Pfizer, Inc. "Pfizer to Discontinue Sumanirole Development Program". Parkinson's Disease Foundation.

[1]

[2]

[3]

[4]

[5]

[6]

See also

References